Adherence Monitor for Substance Use Disorder Treatment

项目摘要 目前SBIR计划的目的是开发一种新的非侵入性，即时检测 用于接受物质使用障碍治疗的患者的装置。新设备将在 能够通过以下方式监测进展并验证患者对处方治疗的依从性 检测尿中释放的复合粘附标记物的存在和水平， 首次提供了能够现场监测药物依从性的装置， 临床试验和患者治疗计划中的治疗结果。我们的发展计划 这种新的即时护理方法使用表面增强拉曼光谱（Sers）， 检测和量化药物依从性示踪剂，利用公司独特的 检测患者尿液中粘附生物标志物的纳米颗粒表面涂层化学 sample.我们的表面增强拉曼技术的一个显着优势， 制备的纳米颗粒表面-依赖于分子振动的独特性 用于区分和鉴定尿液中存在的粘附生物标志物的特征- 它不需要样品制备或化学操作来检测生物标志物， 尿样

Project Summary The aim of the present SBIR program is to develop a new noninvasive, point-of-care testing device for patients undergoing treatment for substance use disorder. The new device will be capable of monitoring the progress and verifying patient adherence to prescribed treatment by detecting the presence and level of a compounded adherence marker released in the urine, providing for the first time a device capable of at-site monitoring of medication adherence for treatment outcome in clinical trials and patient treatment programs. Our program to develop this new point-of-care approach uses surface-enhanced Raman spectroscopy (SERS) for detecting and quantifying the medication adherence tracer, utilizing the Company's unique nanoparticle surface-coating chemistry to detect the adherence biomarker in a patient's urine sample. A significant advantage of our surface-enhanced Raman technique on a properly prepared nanoparticle surface -- relying on the uniqueness of the molecular vibrational signature for differentiation and identification of the adherence biomarkers present in urine -- is that it requires no sample preparation or chemical manipulation to detect the biomarker in the urine sample.